Sera Prognostics (SERA) Liabilities and Shareholders Equity (2020 - 2026)
Sera Prognostics' (SERA) quarterly Liabilities and Shareholders Equity came in at $93.5 million in Q1 2026, down 20.85% YoY from $118.2 million in Q1 2025, and down 8.23% on a QoQ basis from $101.9 million in Q4 2025.
Sera Prognostics (SERA) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Sera Prognostics (SERA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $93.5 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 20.85% year-over-year to $93.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $415.4 million (up 17.15% YoY) and the FY2025 annual result came in at $101.9 million, up 40.45% from the prior year.
- Liabilities and Shareholders Equity retreated to $93.5 million in Q1 2026, from $101.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $134.9 million in Q1 2022 to a low of $72.6 million in Q4 2024.
- A 5-year average of $102.4 million and a median of $101.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slipped 24.16% — and 2025, when it soared 40.45%.
- Tracing SERA's Liabilities and Shareholders Equity over 5 years: stood at $116.3 million in 2022, then retreated by 17.96% to $95.4 million in 2023, then retreated by 23.96% to $72.6 million in 2024, then surged by 40.45% to $101.9 million in 2025, then declined by 8.23% to $93.5 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $93.5 million (Q1 2026), $101.9 million (Q4 2025), and $108.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Sera Prognostics | 103.48 Mn | 103.48 Mn | -20,000.00 | 86.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.74 Mn |
| Mar 31, 2026 | 93.54 Mn |
| Dec 31, 2025 | 101.93 Mn |
| Sep 30, 2025 | 108.13 Mn |
| Jun 30, 2025 | 111.83 Mn |
| Mar 31, 2025 | 118.18 Mn |
| Dec 31, 2024 | 72.58 Mn |
| Sep 30, 2024 | 79.00 Mn |
| Jun 30, 2024 | 84.86 Mn |
| Mar 31, 2024 | 89.89 Mn |
| Dec 31, 2023 | 95.44 Mn |
| Sep 30, 2023 | 90.06 Mn |
| Jun 30, 2023 | 96.68 Mn |
| Mar 31, 2023 | 105.61 Mn |
| Dec 31, 2022 | 116.33 Mn |
| Sep 30, 2022 | 116.56 Mn |
| Jun 30, 2022 | 125.06 Mn |
| Mar 31, 2022 | 134.87 Mn |
| Dec 31, 2021 | 147.03 Mn |
| Sep 30, 2021 | 153.69 Mn |